Direct cost savings associated with reduction in plasma metagenomic sequencing
Following recognition that our hospital had higher use of plasma metagenomic next-generation sequencing than our peers, we implemented a process for approval by infectious diseases before test collection. This intervention is calculated to result in a direct cost savings of $79,505-$84,057/year, driven mainly by reduced laboratory costs.
Authors
- Ravi R. Jhaveri (ORCID: https://orcid.org/0000-0001-9921-0419)
- Neil Jordan (ORCID: https://orcid.org/0000-0001-8467-822X)
- Shannon Haymond
- Caitlin Naureckas Li (ORCID: https://orcid.org/0000-0003-4737-1661)
- David Koscinski
Institutions
- Northwestern University (US)
- Lurie Children's Hospital (US)
- Lurie Children's Hospital (US)
Publication Details
- Journal
- Infection Control and Hospital Epidemiology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1017/ice.2025.10329
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94